AITC for Health & Longevity - Quick Reference Sheet

AITC for Health & Longevity

Created on 09/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

AITC is the sharp compound released when mustard, horseradish or wasabi is crushed. The same reactivity that switches on the body's protective and detoxification genes also makes it a powerful irritant. Given alone to people, results have been unremarkable or negative. Fresh preparation appears to matter more than capsules; the thyroid worry appears to dissolve where iodine intake is adequate. (Full Review)

Protocol

Dietary route (the best-characterised exposure)
5–15 g
Freshly grated horseradish or prepared mustard, delivering roughly 12–74 micromoles of isothiocyanate, the range in which human absorption has been measured.
Licensed herbal combination, prophylaxis
Twice daily
Nasturtium–horseradish tablet: twice daily for 90 days, or prophylactic dosing continued to six months. The regimen with placebo-controlled support.
Preparation matters more than dose
Raw, or added after cooking
Cooking destroys the plant enzyme, cutting conversion to roughly a quarter. Taken with meals in divided doses, which lowers peak mucosal concentration.
Time to effect
Recurrent urinary tract infection
90 days
The recurrence-prophylaxis trials required 90 days to separate from placebo.
Acute bronchitis symptoms
Day 3
The bronchitis trial showed symptom benefit by day three, and the advantage persisted to day ten.
Oral malodour
Immediate
Volatile sulfur compounds fell immediately after chewing, with the effect declining over the following three hours.

Benefits

Contraindications
  • Confirmed mustard, horseradish or wasabi allergy
  • Children under 6 years
  • Pregnancy and breastfeeding
  • Active peptic ulcer disease or acute inflammatory bowel disease flare
  • Severe kidney impairment (filtration rate below 30 mL/min/1.73 m²)
  • Undiluted essential oil applied to skin
Key Interactions
  • Warfarin and other narrow-margin CYP2C9 substrates (phenytoin, glipizide)
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)
  • Acid-suppressing drugs (omeprazole, famotidine)
  • Antibiotics for urinary or respiratory infection (co-trimoxazole, nitrofurantoin)
  • Levothyroxine and antithyroid drugs
  • Other pungent TRPA1-activating supplements (cinnamaldehyde, garlic allicin, ginger, capsaicin)
  • Supplements with additive antiplatelet effect (fish oil, garlic, ginkgo, high-dose vitamin E)
  • Sulforaphane and broccoli-sprout products

Risk & Side Effects

  • High: Mucosal, ocular and cutaneous irritation
  • Medium: Allergic contact dermatitis; allergic reaction to the mustard source material
  • Low: Interference with thyroid function
  • Speculative: Transient DNA strand breaks after ingestion; bladder lining overgrowth at high doses in rats; interference with drug clearance via CYP2C9

Monitoring

Marker Target Why
Thyroid-stimulating hormone 0.5–2.0 mIU/L Detects any thyroid suppression from cabbage-family compounds
Free thyroxine 1.0–1.5 ng/dL Confirms whether an abnormal thyroid-stimulating hormone reflects real hormone change
Urinary iodine concentration 100–200 micrograms/L Identifies the deficiency state in which a thyroid effect becomes plausible
Urinalysis with microscopy No blood, no atypical cells Screens the organ where AITC concentrates and where rodent tumours appeared
Alanine aminotransferase 10–26 U/L (men), 8–22 U/L (women) Detects liver stress from a compound metabolised almost entirely in the liver
International normalised ratio Target set by the prescriber, typically 2.0–3.0 Captures the one drug interaction with a plausible mechanism, in warfarin users
Urinary dithiocarbamate metabolites No established target; change from the individual's own baseline Confirms the product is actually delivering absorbed isothiocyanate

Cadence: Thyroid-stimulating hormone and free thyroxine at 8–12 weeks, then every 6–12 months while use continues; urinalysis repeated at 6 months; in warfarin users, clotting time at 2 and 6 weeks after any dose change. For food-level intake, no laboratory testing is warranted at all.

Qualitative Assessment

  • Frequency and severity of the target symptom — confirmed urinary infections per six months, or days of cough per episode
  • Gastric burning, reflux or new upper-abdominal discomfort, the earliest sign the dose is too high
  • Nasal and ocular irritation on dosing, and whether it fades with continued use
  • Perceived pungency, which is genetically variable and is not a reliable proxy for absorbed dose
  • Skin changes on the hands in anyone handling the raw material regularly
  • Energy and sleep quality, mainly to detect evening dosing causing nocturnal reflux